Page 23 - Demo

General introduction 211References1. European Union. Regul. N°141/2000 Eur. Parliam. Counc. 16 December 1999 orphan Med. Prod. 2000.2. Rode J. Rare diseases: understanding this public health priority. Paris: EURORDIS 2005.3. Castrén E, Elgersma Y, Maffei L, Hagerman R. Treatment of Neurodevelopmental disorders in Adulthood. J. Neurosci. 2012;32(41).4. Levy G, Barak B. Postnatal therapeutic approaches in genetic neurodevelopmental disorders [Internet]. 2021;3. Available from: https://doi.org/10.4103/1673-5374.293133.5. Ellison JW, Rosenfeld JA, Shaffer LG. Genetic basis of intellectual disability. Annu. Rev. Med. 2013;64.6. Leonard H, Wen X. The epidemiology of mental retardation: Challenges and opportunities in the new millennium. Ment. Retard. Dev. Disabil. Res. Rev. 2002;8(3).7. Schalock RL, Luckasson R, Tassé MJ. An overview of intellectual disability: Definition, diagnosis, classification, and systems of supports (12th ed.). Am. J. Intellect. Dev. Disabil. 2021;126(6).8. Maia N, Nabais Sá MJ, Melo-Pires M, et al. Intellectual disability genomics: current state, pitfalls and future challenges. BMC Genomics 2021;22(1).9. Kvarnung M, Nordgren A. Intellectual disability & rare disorders: A diagnostic challenge. In: Advances in Experimental Medicine and Biology. 2017.10. Cannizzo S, Lorenzoni V, Palla I, et al. Rare diseases under different levels of economic analysis: Current activities, challenges and perspectives. RMD Open 2018;4.11. Kostanjsek N. Use of the International Classification of Functioning, Disability and Health (ICF) as a conceptual framework and common language for disability statistics and health information systems. In: BMC Public Health. 2011.12. Paschos D. Intellectual Disability: Understanding its Development, Causes, Classifications, Evaluation, and Treatment. Child Adolesc. Ment. Health 2008;13(4).13. Sappok T, Diefenbacher A, Winterholler M. The Medical Care of People With Intellectual Disability. Dtsch. Arztebl. Int. 2019.14. Presson AP, Partyka G, Jensen KM, et al. Current estimate of down syndrome population prevalence in the United States. J. Pediatr. 2013;163(4).15. von Scheibler ENMM, van Eeghen AM, de Koning TJ, et al. Parkinsonism in Genetic Neurodevelopmental Disorders: A Systematic Review. Mov. Disord. Clin. Pract. 2023;10(1).16. Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol. 2015.17. Roth J, Roach ES, Bartels U, et al. Subependymal giant cell astrocytoma: Diagnosis, screening, and treatment. Recommendations from the international tuberous sclerosis complex consensus conference 2012. Pediatr. Neurol. 2013;49(6).18. Huisman S, Mulder P, Kuijk J, et al. Self-injurious behavior. Neurosci. Biobehav. Rev. 2018;84:483–491.19. Berg K, Arron K, Burbidge C, et al. Carer-Reported Contemporary Health Problems in People With Severe and Profound Intellectual Disability and Genetic Syndromes. J. Policy Pract. Intellect. Disabil. 2007;4(2).20. De Villiers J, Porteous M. Genetic testing of adults with intellectual disability. Psychiatrist 2012;36(11)21. Morant AV, Jagalski V, Vestergaard HT. Labeling of Disease-Modifying Therapies for Neurodegenerative Disorders. Front. Med. 2019.22. Vernon HJ. Inborn errors of metabolism: Advances in diagnosis and therapy. JAMA Pediatr. 2015.23. Jacquemont S, Berry-Kravis E, Hagerman R, et al. The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl). 2014.Annelieke Muller sHL.indd 21 14-11-2023 09:07